Connecting Fundraising with Marketing

Due to the rising costs associated with online-only startups in recent years, an increasing number of online-only businesses are adopting a bold new strategy: opening physical stores. This new trend is a departure from the traditional business model of starting online first and then expanding into physical locations. The shift towards brick-and-mortar presence can be seen in many online companies, from Warby Parker—the eyeglass company—to the beauty brand Glossier. These companies are setting up physical stores to expand their customer base, bring their products to more people, and ultimately generate more revenue. The physical stores also offer customers the chance to experience the company’s products in person before buying. This can help combat the issue of returns, which is an expensive problem faced by many online retailers. Additionally, physical stores offer opportunities for companies to engage with their customers in person, gaining invaluable insights into their preferences and better understanding the needs of their target market. A trend to follow!

The European tech scene is not as healthy as Silicon Valley, and there is evidence that the growth of the tech industry is stagnating in many countries. Some of the main reasons cited as to why this is the case include limited availability of funds from venture capital and slow government regulations. The lack of investment capital is also exacerbating the issue, as it limits the ability of companies to scale and expand their operations. Furthermore, the talent pool in Europe is generally less experienced than in the US, meaning that the likelihood of success is lower for new businesses. Thus, fewer startups are achieving the status of ‘unicorn’ (a term used to describe a technology startup valued at $1 billion or more). Until these fundamental structural issues are addressed, it is likely that European unicorns will continue to stagnate.

Rodller has a wide scale of Mandates to Source Investment Deals for its Venture Capital Partners. But one mandate was not yet fully addressed. Biotech. This industry is tricky and requires deep knowledge to assess the credibility of each opportunity. We Partnered with a VC specialist that can assist us in Sourcing valid deals, garantueeing continuous quality for our VC Customers, that do have the Biotech in their Mandate. The global venture capital investments in biotechnology have grown substantially over the past decade. The value of venture capital funding was $26.29 billion in 2019, which was a nearly four-fold increase from $6.6 billion in 2010. The biotechnology sector attracted most of the investment within the healthcare sector, followed by medical devices, digital health, and healthcare services. These investments have been increasing year over year, with biomedical and IT/healthcare leading the way. The most prominent VC investors in biotechnology have been large venture capital firms such as Kleiner Perkins, Andreessen Horowitz, BioVentures, New Enterprise Associates, Arch Venture Partners, Versant Ventures, and Abingworth. Other venture capital investors active in biotechnology include Sofinnova, Venrock, Google Ventures, and OrbiMed. U.S. based venture capital firms have been the most active investors in biotech ventures, particularly in the preclinical and clinical-stage categories, pouring a total of $17.3 billion into biotech companies from 2010 to 2019. However, interest from European and Asian investors is also growing, and venture capital firms located in these regions have made investments in biotechnology totaling nearly $4 billion in this same period. Rodller is proud to have a say in this space.

Privacy Policy | Terms & Conditions | Unsubscribe

160 Robinson Road, 068914, Singapore

© All Rights Reserved 2023